Personalized Medicine Market Size, Share, Future Analysis, 2026-2034

Market Overview

According to fortune business insights, the global personalized medicine market size was valued at USD 214.44 billion in 2025. The market is projected to grow from USD 233.87 billion in 2026 to USD 587.02 billion by 2034, exhibiting a CAGR of 12.19% during the forecast period. North America dominated the personalized medicine market with a market share of 39.11% in 2025.

These insights have been deep-dived into in a recent research report, titled “Personalized Medicine Market, 2026-2034.”

The analysis shows that top companies are investing more in personalized medicine because of wider acceptance of genomic testing and heightened demand for biomarker-driven targeted therapies. For example, major players like F. Hoffmann-La Roche Ltd and Thermo Fisher Scientific Inc. are focusing on extensive genomic profiling, liquid biopsy, and AI-driven data platforms. This trend indicates strong demand for personalized medicine worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd (Switzerland)

• Myriad Genetics, Inc. (U.S.)

• Thermo Fisher Scientific Inc. (U.S.)

• AstraZeneca (U.K.)

• Guardant Health, Inc. (U.S.)

• Agilent Technologies Inc. (U.S.)

• Pfizer Inc. (U.S.)

• Novartis AG (Switzerland)

• Illumina Inc. (U.S.)

• Bristol-Myers Squibb Company (U.S.)

Segments

Expanding Use of Biomarker-Guided Therapies to Propel Therapeutics Segment GrowthBased on offering, the market is divided into diagnostics & testing, therapeutics, software & data analytics, and others. The therapeutics segment holds the largest market share and dominates the market owing to the high commercial potential of targeted therapies and the growing adoption of biomarker-driven treatment selection.

Wider Use of Genomic Profiling to Drive Genomics & Molecular Testing Segment ExpansionBy technology, the market is categorized into genomics & molecular testing, biomarker-based profiling, liquid biopsy, and others. The genomics & molecular testing segment is leading the market as it plays a central role in identifying disease-causing mutations and therapy-response markers before treatment begins.

Rising Cancer Burden to Dominate the Market Due to Wider Use of Biomarker TestingBased on application, the market is segmented into oncology, rare & genetic diseases, neurology, cardiology, infectious diseases, and others. The oncology segment holds the largest market share owing to the significant global impact of cancer and the rapid integration of companion diagnostics and targeted treatments into standard care.

Strong Integration of Workflows to Dominate the Market Due to its Role as a Central HubBased on end user, the market is split into hospitals, specialty clinics, diagnostic laboratories, and others. The hospitals segment leads market growth owing to its role as the primary hub for sophisticated diagnosis, biomarker analysis, treatment planning, and the delivery of targeted therapies.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Get More Info: https://www.fortunebusinessinsights.com/industry-reports/personalized-medicine-market-100350

Report Coverage

The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.

• Comprehensive insights into regional developments.

• List of major industry players.

• Key strategies adopted by the market players.

• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & Restraints

Increasing Prevalence of Chronic and Genetic Diseases to Propel Market GrowthThe rapid increase in chronic and genetic conditions has raised the demand for personalized medicine, as it broadens the patient population requiring earlier diagnosis, risk assessment, and customized treatment. This drives the need for biomarker testing, molecular diagnostics, and targeted therapies, boosting market growth.

However, the high cost of personalized treatments, including targeted biologics and cell/gene therapies, and the additional expense of companion diagnostics may limit patient access and slow market adoption.

Regional Insights

Advanced Genomics Infrastructure in the U.S. Propels Market Growth in North AmericaNorth America holds the dominant personalized medicine market share and is projected to experience growth during the forecast period. The region’s growth is attributed to the strong adoption of biomarker-based testing, high use of targeted therapies, and large-scale precision medicine research programs.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to rapid healthcare modernization, rising investments in precision medicine, and strong policy support in key markets such as China, Japan, and Singapore.

Personalized Medicine Market Future Growth:

The personalized medicine market is experiencing robust growth, fueled by advancements in genomics, the increasing prevalence of chronic diseases, and a strong shift toward biomarker-driven targeted therapies. Today's healthcare providers are increasingly drawn to treatments tailored to individual patient profiles, utilizing companion diagnostics, liquid biopsy, and AI-driven data analytics to improve outcomes. Additionally, there's a growing expansion of personalized approaches from oncology into other areas like cardiology, neurology, and rare diseases. The integration of AI-powered platforms and digital health tools is also a key growth driver. While North America continues to dominate the market, the Asia-Pacific region is seeing a surge in demand, driven by healthcare modernization and rising research investments.

Competitive Landscape

Growing Adoption of AI-Integrated Platforms and Strategic Collaborations to Propel Market GrowthThe market features prominent players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and AstraZeneca. These leading companies are accelerating growth through strategic initiatives such as expanding their capabilities in genomic testing, liquid biopsy, and companion diagnostics, as well as forming collaborations to develop AI-enabled interpretation platforms. Their proactive approach to innovation continues to fuel the market’s momentum.

Key Industry Development

• March 2026: Natera announced the commercial launch of Zenith Genomics, a test designed to shorten diagnostic journeys for patients with rare and ultra-rare diseases.

• March 2026: Tempus AI and Merck announced an expanded multi-year collaboration to accelerate precision medicine biomarker discovery.